Revise, Edit, Delete: Gene Editing for a Healthier Future
What if we could remove diseases at the cellular level to stop them from growing before they begin? Specific Biologics, a JLABS @ Toronto company recently selected as one of the first BLUE KNIGHT™ companies, is aiming to do just that. Join this session to hear from Brent Stead, CEO, of Specific Biologics, who will present on how the company’s gene editing platform technology differs from the well-known CRISPR-Cas9, and could more accurately correct errors at the genetic level in cells inside the body.
Tuesday, October 13, 2020
Share this page